SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

25 Jan 2022 Evaluate
The December 2021 quarter revenue stood at Rs. 39547.90 millions, up 5.98% as compared to Rs. 37315.50 millions during the corresponding quarter last year.A meek growth of 4.56% was reported for the quarter ended December 2021 to Rs. 7308.30  millions from Rs. 6989.30 millions.The company reported a good operating profit of 11129.80 millions compared to 10922.70 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 39547.90 37315.50 5.98 119072.30 106674.60 11.62 139005.80 126591.50 9.81
Other Income 730.00 961.20 -24.05 3503.90 1809.50 93.64 2302.80 8928.50 -74.21
PBIDT 11129.80 10922.70 1.90 35186.80 32528.10 8.17 39518.40 36001.40 9.77
Interest 55.50 103.30 -46.27 211.50 362.30 -41.62 450.70 360.50 25.02
PBDT 11074.30 10819.40 2.36 34975.30 32165.80 8.73 39067.70 35640.90 9.61
Depreciation 1339.50 1345.70 -0.46 4099.00 4191.00 -2.20 5561.10 5997.80 -7.28
PBT 9734.80 9473.70 2.76 30876.30 27974.80 10.37 33506.60 29643.10 13.03
TAX 2426.50 2484.40 -2.33 7826.60 7426.10 5.39 8823.80 6461.40 36.56
Deferred Tax -159.10 -31.60 403.48 -276.40 -290.90 -4.98 -220.00 1001.80 -121.96
PAT 7308.30 6989.30 4.56 23049.70 20548.70 12.17 24682.80 23181.70 6.48
Equity 1613.60 1612.90 0.04 1613.60 1612.90 0.04 1612.90 1612.50 0.02
PBIDTM(%) 28.14 29.27 -3.86 29.55 30.49 -3.09 28.43 28.44 -0.03

Cipla Share Price

1232.90 4.00 (0.33%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×